NL
DE
A research group from Radboudumc and UMC Utrecht is to investigate laser treatment of a rare brain tumor, glioblastoma. 3.9 million euros has been made available for the research by Zorginstituut Nederland and ZonMw, under the auspices of the Subsidy Scheme for Promising Care.
The research group, which includes technical physician Kristian Overduin, professor of Health Evidence Maroeska Rovers, associate professor of Health Evidence Janneke Grutters, neurosurgeon Mark ter Laan of the Radboudumc, and neurosurgeon Pieter van Eijsden of UMC Utrecht, will receive 3.9 million euros for research into brain tumors. In the Netherlands, 1,100 people contract glioblastoma, a rare malignant brain tumor, each year. This is a brain tumor in which the average life span after diagnosis is up to two years. In thirty percent of patients, the tumor cannot be removed with surgery. "With Stereotactic Laser Ablation (SLA), we can offer these patients a new option," said Radboudumc neurosurgeon Mark ter Laan, who is leading the study. "This is a minimally invasive surgery that allows the targeted burning away of brain tumors with laser light. The procedure takes place in an MRI scanner." The surgeon thus has direct images of the brain tumor during the treatment, preventing damage to surrounding tissue with important functions. Research abroad shows hopeful results.
Neurosurgeon Pieter van Eijsden of UMC Utrecht: "Because brain tumors are quite exceptional, relatively little is invested in this research compared to other tumors. That makes this award extra special." The Radboudumc and UMC Utrecht will now investigate the effect, complications and costs of this treatment for the first time in the Netherlands, supported by the National Neuro-Oncology Working Group and the patient association hersenletsel.nl. Also the effect on survival and quality of life will be investigated. The study should show whether SLA is indeed a better treatment for patients with glioblastoma where surgery is not possible.
-
Want to know more about these subjects? Click on the buttons below for more news.
RIHSHealth EvidenceNeurosurgery Radiology & Nuclear Medicine Urological cancersReconstructive and regenerative medicine
Related news items
Body composition is more important than BMI for renal cancer survival rates
11 January 2022 Body composition is important for survival rates in renal cell cancer. Research from the Radboudumc shows that low muscle quality and low organ fat are associated with poor survival. This involves different stages of renal cancer, ranging from stage I-III to stage IV. read more
Turbo Grants for four medical-technical research projects
19 October 2021 Four TURBO grants were recently awarded to new technical-medical research proposals. The grants are part of the TURBO program, a collaboration between the University of Twente (TechMed Centre) and the Radboudumc. read more
Plugging the gap ZonMw/Health Holland grant
3 March 2020 RIMLS en RIHS researchers Willeke Daamen, Frank Vandenbussche, Joris van Drongelen, Toin van Kuppevelt and Janneke Grutters have been granted 1.3 million euro for the development and evaluation of a new technology to prevent premature rupture of fetal membranes (iPPROM). read more
Jurgen Fütterer appointed Professor of Image-Guided Oncological Interventions
26 February 2020 RIHS researcher Fütterer is an interventional radiologist and an expert in the field of cancer imaging techniques, image-guided interventions and robotics. He is also Professor at the Robotics and Mechatronics Group at the University of Twente. read more
SPL Medical starts clinical trial with contrast agent ferrotran
11 February 2020 SPL Medical is starting an international registration study for its contrast agent Ferrotran. The study is being conducted in ten hospitals in Germany, Switzerland and the Netherlands. RIHS researcher Jelle Barentsz discovered the value of this drug in patients with lymph node metastases. read more
